A comparative study on the efficacy of low-carb diet and orlistat in the treatment of nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027172

Enrollment

Unknown

Registered

2019-11-03

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

Experimental group 1:Orlistat 120mg, 3 times a day

Experimental group 2:low-carbon diet

Control group:basic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Clinically and pathologically diagnosed with NAFLD on the basis of Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease of China; 2. aged from 18~60 years; 3. BMI >=27; 4. Quantitative liver fat content >=10% by magnetic resonance (DIXON/IDEAL water-lipid separation technique); 5. Able to and willing to give informed consent, willing to comply with the program requirements.

Exclusion criteria

Exclusion criteria: 1. drug allergy history; 2. Alcohol intake >20g/day; 3. ALT >=120U/L; 4. accompanied with other liver diseases such as chronic viral hepatitis, alcoholic liver disease, autoimmune liver disease, toxic liver damage and drug-induced liver damage, Wilson's disease, and other metabolic and hereditary liver diseases; 5. accompanied with end-stage liver diseases such as cirrhosis or liver cancer; 6. women in pregnancy or lactation; 7. accompanied with thyroid disease, diabetes, pancreatic disease, malabsorption syndrome, organic heart disease, respiratory diseases, hematological system diseases or kidney disease; 8. previous abdominal surgery; 9. have taken steatohepatitis treatments within 3 months; 10. have taken drugs for metabolic disorder; 11. have received transfusions within 3 months; 12. have taken steroid therapy within 6 months; 13. Exercise more than 2 hours a day; 14. There are metal devices in the body or can not cooperate with the completion of magnetic resonance examination.

Design outcomes

Primary

Measure	Time frame
hepatic fat fraction;liver pathology;Hepatic fat quantification;liver stiffness;Haematological index;	—

Contacts

Public ContactBIHUI ZHONG

Division of Gastroenterology of The First Affiliated Hospital of Sun Yat-sen University

2425349025@qq.com+86 18688884506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026